Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Rheumatologists Cite Improved Health-Related Quality of Life, Improved Effect in Disease Activity among Unmet Needs, According to Findings from Decision Resources Group
BURLINGTON, Mass., April 28, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and EU5 rheumatologists agree that new therapies for the treatment of moderate to severe systemic lupus erythematosus (SLE) that offer improved effect on disease activity and renal organ domain scores over current therapies would be well received and poised for strong uptake. This finding reflects thought leader opinion that IV belimumab (GlaxoSmithKline's Benlysta) offers only modest efficacy on these attributes, while therapies typically used to treat moderate to severe renal manifestations are associated with a risk of serious side effects that limit their widespread use in patients with early stage renal involvement. Based on currently available clinical data and thought leader opinion, UCB's emerging therapy epratuzumab has the potential to offer improvements over belimumab in health-related quality of life and time to response, as well as an acceptable safety profile.
Other key findings from the DecisionBase 2014 report entitled Systemic Lupus Erythematosus: Significant Market Opportunity Awaits Therapies Offering Improvements in Efficacy over IV Belimumab for the Moderate to Severe Patient Segment:
Comments from Decision Resources Group Analyst Alexandra Makarova, M.D., Ph.D.:
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.